Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and / or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and / or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
Not Available
III
Rexer, Brent
NCT03529110
VICCBRE18126

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients with Newly Diagnosed WNT-Driven Medulloblastoma

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT) / Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.
Not Available
II
Pastakia, Devang
NCT02724579
COGACNS1422

Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations

This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that have spread to other places in the body (metastatic) and usually cannot be cured or controlled with treatment (refractory). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Not Available
II
Davis, Elizabeth
NCT03212274
VICCMD18129

Compare Fallopian Tube Cells Collected by MAKO 7 With Removed Ovarian / Tubal Tissue to Determine Presence of Malignancy

Prospective, multi-center, non-randomized study to assess the ability of the MAKO 7 device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.
Not Available
N/A
Anderson, Ted
NCT03593681
VICCGYN18131

Provision of Free Varenicline (Chantix) within the Context of a Dedicated Outpatient Tobacco Treatment Clinic (TTC) for Cancer Patients

Not Available
N/A
Tindle, Hilary
VICCTHO18132

Safety and Efficacy of KTE-X19 in Adults With Relapsed / Refractory Chronic Lymphocytic Leukemia

The primary objective of this study is to evaluate the safety (Phase 1) and efficacy (Phase 2) of KTE-X19 in adults with relapsed / refractory chronic lymphocytic leukemia (r / r CLL).
Not Available
I/II
Byrne, Michael
NCT03624036
VICCBMT18134

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression.
Not Available
II
Iams, Wade
NCT03631706
VICCTHO18139

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

This is a Phase 1, open label, multi-center study of intravenously administered DSP-0509 in adult subjects with advance solid tumors that are refractory to standard treatment.
Not Available
I
Not Available
NCT03416335
VICCPHI18141

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer compared to subjects followed on active surveillance as standard of care.
Not Available
III
Barocas, Daniel
NCT03686683
VICCURO18143

Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.
Not Available
II
Oluwole, Olalekan
NCT03761056
VICCBMT18146

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: